Home / News / Pearce IP Blog
In the first Federal Court patent decision handed down in 2024, MSA 4×4 Accessories Pty Ltd failed to establish infringement by Clearview Towing Mirrors Pty Ltd of MSA’s patent to a mountable storage device, commonly used in off-road and trade vehicles.
23 FEB 2024 | EU | Samsung Bioepis Presented Study Results for ustekinumab SB17, Biosimilar to Janssen’s Stelara®, at...
19 JAN 2024 | AU | March a Bumper Month for Biopharma at the Pharmaceutical Benefits Assessment Committee (PBAC) in...
09 FEB 2024 | AU | Biocon Biologics Enter a Five-year Exclusive Partnership with Sandoz in Australia for Trastuzumab...
On 24 January 2024 New Zealand introduced a new IP Bill for Geographical Indications (GIs). The bill will amend NZ law...
26 JAN 2024 | SG | AbbVie to Expand Biologics Manufacturing Facility in Singapore with US$223M Investment AbbVie...
19 JAN 2024 | US | Alvotech Provides Update on FDA Facility Inspection for AVT02 and AVT04 Alvotech announced that its...
12 JAN 2024 | EU | Celltrion Wins European Bids for Yuflyma® (adalimumab) and Remsima® (infliximab) Korea Biomedical...
05 JAN 2024 | AU | Celltrion’s Remsima SC®, Biobetter to Remsima®, Biosimilar to Janssen’s Remicade® (infliximab),...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
15 DEC 2023 | KR | Approval Alert: LG Chem’s Xelenka® Biosimilar to AbbVie’s Humira® (adalimumab) Approved in Korea...
08 DEC 2023 | US | FDA Approves First Cell-Based Gene Therapies Casgevy® and Lyfgenia® to Treat Sickle Cell Disease...
01 DEC 2023 | US | Celltrion Files BLA for Interchangeable Prolia® (Denosumab) Biosimilar with the FDA The Korea...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
24 NOV 2023 | Celltrion Applies For EU Approval of CT-P42, Biosimilar to Regeneron’s Eylea® (aflibercept) Celltrion...